A	O
versatile	O
system	O
for	O
rapid	O
multiplex	O
genome	B:C4279981
-	I:C4279981
edited	I:C4279981
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
T	O
cell	I:C0039194
generation	O
.	O

A	O
versatile	O
system	O
for	O
rapid	O
multiplex	O
genome	O
-	I:C4279981
edited	I:C4279981
chimeric	B:C4039583
antigen	I:C4039583
receptor	I:C4039583
T	O
cell	I:C0039194
generation	O
.	O

A	O
versatile	O
system	O
for	O
rapid	O
multiplex	O
genome	O
-	I:C4279981
edited	I:C4279981
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
T	B:C0039194
cell	I:C0039194
generation	O
.	O

The	O
therapeutic	B:C0087111
potential	O
of	O
CRISPR	O
system	O
has	O
already	O
been	O
demonstrated	O
in	O
many	O
instances	O
and	O
begun	O
to	O
overlap	O
with	O
the	O
rapidly	O
expanding	O
field	O
of	O
cancer	O
immunotherapy	I:C0278348
,	O
especially	O
on	O
the	O
production	O
of	O
genetically	O
modified	I:C4277689
T	O
cell	I:C0034790
receptor	I:C0034790
or	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
(	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
)	O
T	O
cells	I:C0039194
.	O

The	O
therapeutic	O
potential	O
of	O
CRISPR	B:C3658200
system	O
has	O
already	O
been	O
demonstrated	O
in	O
many	O
instances	O
and	O
begun	O
to	O
overlap	O
with	O
the	O
rapidly	O
expanding	O
field	O
of	O
cancer	O
immunotherapy	I:C0278348
,	O
especially	O
on	O
the	O
production	O
of	O
genetically	O
modified	I:C4277689
T	O
cell	I:C0034790
receptor	I:C0034790
or	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
(	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
)	O
T	O
cells	I:C0039194
.	O

The	O
therapeutic	O
potential	O
of	O
CRISPR	O
system	O
has	O
already	O
been	O
demonstrated	O
in	O
many	O
instances	O
and	O
begun	O
to	O
overlap	O
with	O
the	O
rapidly	O
expanding	O
field	O
of	O
cancer	B:C0278348
immunotherapy	I:C0278348
,	O
especially	O
on	O
the	O
production	O
of	O
genetically	O
modified	I:C4277689
T	O
cell	I:C0034790
receptor	I:C0034790
or	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
(	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
)	O
T	O
cells	I:C0039194
.	O

The	O
therapeutic	O
potential	O
of	O
CRISPR	O
system	O
has	O
already	O
been	O
demonstrated	O
in	O
many	O
instances	O
and	O
begun	O
to	O
overlap	O
with	O
the	O
rapidly	O
expanding	O
field	O
of	O
cancer	O
immunotherapy	I:C0278348
,	O
especially	O
on	O
the	O
production	O
of	O
genetically	B:C4277689
modified	I:C4277689
T	O
cell	I:C0034790
receptor	I:C0034790
or	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
(	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
)	O
T	O
cells	I:C0039194
.	O

The	O
therapeutic	O
potential	O
of	O
CRISPR	O
system	O
has	O
already	O
been	O
demonstrated	O
in	O
many	O
instances	O
and	O
begun	O
to	O
overlap	O
with	O
the	O
rapidly	O
expanding	O
field	O
of	O
cancer	O
immunotherapy	I:C0278348
,	O
especially	O
on	O
the	O
production	O
of	O
genetically	O
modified	I:C4277689
T	B:C0034790
cell	I:C0034790
receptor	I:C0034790
or	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
(	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
)	O
T	O
cells	I:C0039194
.	O

The	O
therapeutic	O
potential	O
of	O
CRISPR	O
system	O
has	O
already	O
been	O
demonstrated	O
in	O
many	O
instances	O
and	O
begun	O
to	O
overlap	O
with	O
the	O
rapidly	O
expanding	O
field	O
of	O
cancer	O
immunotherapy	I:C0278348
,	O
especially	O
on	O
the	O
production	O
of	O
genetically	O
modified	I:C4277689
T	O
cell	I:C0034790
receptor	I:C0034790
or	O
chimeric	B:C4039583
antigen	I:C4039583
receptor	I:C4039583
(	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
)	O
T	O
cells	I:C0039194
.	O

The	O
therapeutic	O
potential	O
of	O
CRISPR	O
system	O
has	O
already	O
been	O
demonstrated	O
in	O
many	O
instances	O
and	O
begun	O
to	O
overlap	O
with	O
the	O
rapidly	O
expanding	O
field	O
of	O
cancer	O
immunotherapy	I:C0278348
,	O
especially	O
on	O
the	O
production	O
of	O
genetically	O
modified	I:C4277689
T	O
cell	I:C0034790
receptor	I:C0034790
or	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
(	O
chimeric	B:C4039583
antigen	I:C4039583
receptor	I:C4039583
)	O
T	O
cells	I:C0039194
.	O

The	O
therapeutic	O
potential	O
of	O
CRISPR	O
system	O
has	O
already	O
been	O
demonstrated	O
in	O
many	O
instances	O
and	O
begun	O
to	O
overlap	O
with	O
the	O
rapidly	O
expanding	O
field	O
of	O
cancer	O
immunotherapy	I:C0278348
,	O
especially	O
on	O
the	O
production	O
of	O
genetically	O
modified	I:C4277689
T	O
cell	I:C0034790
receptor	I:C0034790
or	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
(	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
)	O
T	B:C0039194
cells	I:C0039194
.	O

Efficient	O
genomic	B:C0017428
disruption	O
of	O
multiple	O
gene	O
loci	I:C0678933
to	O
generate	O
universal	O
donor	O
cells	I:C0007634
,	O
as	O
well	O
as	O
potent	O
effector	O
T	I:C3641722
cells	I:C3641722
resistant	O
to	O
multiple	O
inhibitory	O
pathways	O
such	O
as	O
PD	O
-	I:C1418401
1	I:C1418401
and	O
CTLA4	O
is	O
an	O
attractive	O
strategy	O
for	O
cell	O
therapy	I:C0302189
.	O

Efficient	O
genomic	O
disruption	O
of	O
multiple	O
gene	B:C0678933
loci	I:C0678933
to	O
generate	O
universal	O
donor	O
cells	I:C0007634
,	O
as	O
well	O
as	O
potent	O
effector	O
T	I:C3641722
cells	I:C3641722
resistant	O
to	O
multiple	O
inhibitory	O
pathways	O
such	O
as	O
PD	O
-	I:C1418401
1	I:C1418401
and	O
CTLA4	O
is	O
an	O
attractive	O
strategy	O
for	O
cell	O
therapy	I:C0302189
.	O

Efficient	O
genomic	O
disruption	O
of	O
multiple	O
gene	O
loci	I:C0678933
to	O
generate	O
universal	O
donor	B:C0007634
cells	I:C0007634
,	O
as	O
well	O
as	O
potent	O
effector	O
T	I:C3641722
cells	I:C3641722
resistant	O
to	O
multiple	O
inhibitory	O
pathways	O
such	O
as	O
PD	O
-	I:C1418401
1	I:C1418401
and	O
CTLA4	O
is	O
an	O
attractive	O
strategy	O
for	O
cell	O
therapy	I:C0302189
.	O

Efficient	O
genomic	O
disruption	O
of	O
multiple	O
gene	O
loci	I:C0678933
to	O
generate	O
universal	O
donor	O
cells	I:C0007634
,	O
as	O
well	O
as	O
potent	O
effector	B:C3641722
T	I:C3641722
cells	I:C3641722
resistant	O
to	O
multiple	O
inhibitory	O
pathways	O
such	O
as	O
PD	O
-	I:C1418401
1	I:C1418401
and	O
CTLA4	O
is	O
an	O
attractive	O
strategy	O
for	O
cell	O
therapy	I:C0302189
.	O

Efficient	O
genomic	O
disruption	O
of	O
multiple	O
gene	O
loci	I:C0678933
to	O
generate	O
universal	O
donor	O
cells	I:C0007634
,	O
as	O
well	O
as	O
potent	O
effector	O
T	I:C3641722
cells	I:C3641722
resistant	O
to	O
multiple	O
inhibitory	O
pathways	O
such	O
as	O
PD	B:C1418401
-	I:C1418401
1	I:C1418401
and	O
CTLA4	O
is	O
an	O
attractive	O
strategy	O
for	O
cell	O
therapy	I:C0302189
.	O

Efficient	O
genomic	O
disruption	O
of	O
multiple	O
gene	O
loci	I:C0678933
to	O
generate	O
universal	O
donor	O
cells	I:C0007634
,	O
as	O
well	O
as	O
potent	O
effector	O
T	I:C3641722
cells	I:C3641722
resistant	O
to	O
multiple	O
inhibitory	O
pathways	O
such	O
as	O
PD	O
-	I:C1418401
1	I:C1418401
and	O
CTLA4	B:C1332802
is	O
an	O
attractive	O
strategy	O
for	O
cell	O
therapy	I:C0302189
.	O

Efficient	O
genomic	O
disruption	O
of	O
multiple	O
gene	O
loci	I:C0678933
to	O
generate	O
universal	O
donor	O
cells	I:C0007634
,	O
as	O
well	O
as	O
potent	O
effector	O
T	I:C3641722
cells	I:C3641722
resistant	O
to	O
multiple	O
inhibitory	O
pathways	O
such	O
as	O
PD	O
-	I:C1418401
1	I:C1418401
and	O
CTLA4	O
is	O
an	O
attractive	O
strategy	O
for	O
cell	B:C0302189
therapy	I:C0302189
.	O

In	O
this	O
study	B:C2603343
,	O
we	O
accomplished	O
rapid	O
and	O
efficient	O
multiplex	O
genomic	O
editing	I:C4279981
,	O
and	O
re-directing	O
T	O
cells	I:C0039194
with	O
antigen	O
specific	I:C0456981
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
via	O
a	O
one	O
-	O
shot	O
CRISPR	O
protocol	O
by	O
incorporation	O
of	O
multiple	O
gRNAs	O
in	O
a	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
lentiviral	O
vector	I:C1520007
.	O

In	O
this	O
study	O
,	O
we	O
accomplished	O
rapid	O
and	O
efficient	O
multiplex	O
genomic	B:C4279981
editing	I:C4279981
,	O
and	O
re-directing	O
T	O
cells	I:C0039194
with	O
antigen	O
specific	I:C0456981
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
via	O
a	O
one	O
-	O
shot	O
CRISPR	O
protocol	O
by	O
incorporation	O
of	O
multiple	O
gRNAs	O
in	O
a	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
lentiviral	O
vector	I:C1520007
.	O

In	O
this	O
study	O
,	O
we	O
accomplished	O
rapid	O
and	O
efficient	O
multiplex	O
genomic	O
editing	I:C4279981
,	O
and	O
re-directing	O
T	B:C0039194
cells	I:C0039194
with	O
antigen	O
specific	I:C0456981
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
via	O
a	O
one	O
-	O
shot	O
CRISPR	O
protocol	O
by	O
incorporation	O
of	O
multiple	O
gRNAs	O
in	O
a	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
lentiviral	O
vector	I:C1520007
.	O

In	O
this	O
study	O
,	O
we	O
accomplished	O
rapid	O
and	O
efficient	O
multiplex	O
genomic	O
editing	I:C4279981
,	O
and	O
re-directing	O
T	O
cells	I:C0039194
with	O
antigen	B:C0456981
specific	I:C0456981
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
via	O
a	O
one	O
-	O
shot	O
CRISPR	O
protocol	O
by	O
incorporation	O
of	O
multiple	O
gRNAs	O
in	O
a	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
lentiviral	O
vector	I:C1520007
.	O

In	O
this	O
study	O
,	O
we	O
accomplished	O
rapid	O
and	O
efficient	O
multiplex	O
genomic	O
editing	I:C4279981
,	O
and	O
re-directing	O
T	O
cells	I:C0039194
with	O
antigen	O
specific	I:C0456981
chimeric	B:C4039583
antigen	I:C4039583
receptor	I:C4039583
via	O
a	O
one	O
-	O
shot	O
CRISPR	O
protocol	O
by	O
incorporation	O
of	O
multiple	O
gRNAs	O
in	O
a	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
lentiviral	O
vector	I:C1520007
.	O

In	O
this	O
study	O
,	O
we	O
accomplished	O
rapid	O
and	O
efficient	O
multiplex	O
genomic	O
editing	I:C4279981
,	O
and	O
re-directing	O
T	O
cells	I:C0039194
with	O
antigen	O
specific	I:C0456981
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
via	O
a	O
one	O
-	O
shot	O
CRISPR	B:C3658200
protocol	O
by	O
incorporation	O
of	O
multiple	O
gRNAs	O
in	O
a	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
lentiviral	O
vector	I:C1520007
.	O

In	O
this	O
study	O
,	O
we	O
accomplished	O
rapid	O
and	O
efficient	O
multiplex	O
genomic	O
editing	I:C4279981
,	O
and	O
re-directing	O
T	O
cells	I:C0039194
with	O
antigen	O
specific	I:C0456981
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
via	O
a	O
one	O
-	O
shot	O
CRISPR	O
protocol	B:C0442711
by	O
incorporation	O
of	O
multiple	O
gRNAs	O
in	O
a	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
lentiviral	O
vector	I:C1520007
.	O

In	O
this	O
study	O
,	O
we	O
accomplished	O
rapid	O
and	O
efficient	O
multiplex	O
genomic	O
editing	I:C4279981
,	O
and	O
re-directing	O
T	O
cells	I:C0039194
with	O
antigen	O
specific	I:C0456981
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
via	O
a	O
one	O
-	O
shot	O
CRISPR	O
protocol	O
by	O
incorporation	O
of	O
multiple	O
gRNAs	B:C0082774
in	O
a	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
lentiviral	O
vector	I:C1520007
.	O

In	O
this	O
study	O
,	O
we	O
accomplished	O
rapid	O
and	O
efficient	O
multiplex	O
genomic	O
editing	I:C4279981
,	O
and	O
re-directing	O
T	O
cells	I:C0039194
with	O
antigen	O
specific	I:C0456981
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
via	O
a	O
one	O
-	O
shot	O
CRISPR	O
protocol	O
by	O
incorporation	O
of	O
multiple	O
gRNAs	O
in	O
a	O
chimeric	B:C4039583
antigen	I:C4039583
receptor	I:C4039583
lentiviral	O
vector	I:C1520007
.	O

In	O
this	O
study	O
,	O
we	O
accomplished	O
rapid	O
and	O
efficient	O
multiplex	O
genomic	O
editing	I:C4279981
,	O
and	O
re-directing	O
T	O
cells	I:C0039194
with	O
antigen	O
specific	I:C0456981
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
via	O
a	O
one	O
-	O
shot	O
CRISPR	O
protocol	O
by	O
incorporation	O
of	O
multiple	O
gRNAs	O
in	O
a	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
lentiviral	B:C1520007
vector	I:C1520007
.	O

High	O
efficient	O
double	O
knockout	B:C0599772
of	O
endogenous	O
TCR	O
and	O
HLA	O
class	I:C0008897
I	I:C0008897
could	O
be	O
easily	O
achieved	O
to	O
generate	O
allogeneic	O
universal	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
T	O
cells	I:C0039194
.	O

High	O
efficient	O
double	O
knockout	O
of	O
endogenous	O
TCR	B:C0034790
and	O
HLA	O
class	I:C0008897
I	I:C0008897
could	O
be	O
easily	O
achieved	O
to	O
generate	O
allogeneic	O
universal	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
T	O
cells	I:C0039194
.	O

High	O
efficient	O
double	O
knockout	O
of	O
endogenous	O
TCR	O
and	O
HLA	B:C0008897
class	I:C0008897
I	I:C0008897
could	O
be	O
easily	O
achieved	O
to	O
generate	O
allogeneic	O
universal	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
T	O
cells	I:C0039194
.	O

High	O
efficient	O
double	O
knockout	O
of	O
endogenous	O
TCR	O
and	O
HLA	O
class	I:C0008897
I	I:C0008897
could	O
be	O
easily	O
achieved	O
to	O
generate	O
allogeneic	O
universal	O
chimeric	B:C4039583
antigen	I:C4039583
receptor	I:C4039583
T	O
cells	I:C0039194
.	O

High	O
efficient	O
double	O
knockout	O
of	O
endogenous	O
TCR	O
and	O
HLA	O
class	I:C0008897
I	I:C0008897
could	O
be	O
easily	O
achieved	O
to	O
generate	O
allogeneic	O
universal	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
T	B:C0039194
cells	I:C0039194
.	O

We	O
also	O
generated	O
Fas	B:C1454645
-	O
resistant	O
universal	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
T	O
cells	I:C0039194
by	O
triple	O
gene	O
disruption	O
.	O

We	O
also	O
generated	O
Fas	O
-	O
resistant	O
universal	O
chimeric	B:C4039583
antigen	I:C4039583
receptor	I:C4039583
T	O
cells	I:C0039194
by	O
triple	O
gene	O
disruption	O
.	O

We	O
also	O
generated	O
Fas	O
-	O
resistant	O
universal	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
T	B:C0039194
cells	I:C0039194
by	O
triple	O
gene	O
disruption	O
.	O

We	O
also	O
generated	O
Fas	O
-	O
resistant	O
universal	O
chimeric	O
antigen	I:C4039583
receptor	I:C4039583
T	O
cells	I:C0039194
by	O
triple	O
gene	B:C0017337
disruption	O
.	O

Simultaneous	O
gene	B:C4277689
editing	I:C4277689
of	O
four	O
gene	O
loci	I:C0678933
using	O
the	O
one	O
-	O
shot	O
CRISPR	O
protocol	O
to	O
generate	O
allogeneic	O
universal	O
T	O
cells	I:C0039194
deficient	O
of	O
both	O
PD1	O
and	O
CTLA	O
-	I:C1332802
4	I:C1332802
was	O
also	O
attempted	O
.	O

Simultaneous	O
gene	O
editing	I:C4277689
of	O
four	O
gene	B:C0678933
loci	I:C0678933
using	O
the	O
one	O
-	O
shot	O
CRISPR	O
protocol	O
to	O
generate	O
allogeneic	O
universal	O
T	O
cells	I:C0039194
deficient	O
of	O
both	O
PD1	O
and	O
CTLA	O
-	I:C1332802
4	I:C1332802
was	O
also	O
attempted	O
.	O

Simultaneous	O
gene	O
editing	I:C4277689
of	O
four	O
gene	O
loci	I:C0678933
using	O
the	O
one	O
-	O
shot	O
CRISPR	B:C3658200
protocol	O
to	O
generate	O
allogeneic	O
universal	O
T	O
cells	I:C0039194
deficient	O
of	O
both	O
PD1	O
and	O
CTLA	O
-	I:C1332802
4	I:C1332802
was	O
also	O
attempted	O
.	O

Simultaneous	O
gene	O
editing	I:C4277689
of	O
four	O
gene	O
loci	I:C0678933
using	O
the	O
one	O
-	O
shot	O
CRISPR	O
protocol	B:C0442711
to	O
generate	O
allogeneic	O
universal	O
T	O
cells	I:C0039194
deficient	O
of	O
both	O
PD1	O
and	O
CTLA	O
-	I:C1332802
4	I:C1332802
was	O
also	O
attempted	O
.	O

Simultaneous	O
gene	O
editing	I:C4277689
of	O
four	O
gene	O
loci	I:C0678933
using	O
the	O
one	O
-	O
shot	O
CRISPR	O
protocol	O
to	O
generate	O
allogeneic	O
universal	O
T	B:C0039194
cells	I:C0039194
deficient	O
of	O
both	O
PD1	O
and	O
CTLA	O
-	I:C1332802
4	I:C1332802
was	O
also	O
attempted	O
.	O

Simultaneous	O
gene	O
editing	I:C4277689
of	O
four	O
gene	O
loci	I:C0678933
using	O
the	O
one	O
-	O
shot	O
CRISPR	O
protocol	O
to	O
generate	O
allogeneic	O
universal	O
T	O
cells	I:C0039194
deficient	O
of	O
both	O
PD1	B:C1418401
and	O
CTLA	O
-	I:C1332802
4	I:C1332802
was	O
also	O
attempted	O
.	O

Simultaneous	O
gene	O
editing	I:C4277689
of	O
four	O
gene	O
loci	I:C0678933
using	O
the	O
one	O
-	O
shot	O
CRISPR	O
protocol	O
to	O
generate	O
allogeneic	O
universal	O
T	O
cells	I:C0039194
deficient	O
of	O
both	O
PD1	O
and	O
CTLA	B:C1332802
-	I:C1332802
4	I:C1332802
was	O
also	O
attempted	O
.	O

